{"product_id":"sclx-marketing-mix","title":"(SCLX) Scilex Holding Company Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Scilex Holding Company 4P's Marketing Mix Analysis summarizes the company’s Product, Price, Place, and Promotion strategy to show how it positions and sells its offerings; the page includes a real preview\/sample of the analysis so you can evaluate style and content. Purchase the full version to download the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZTlido 1.8% lidocaine patch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZTlido 1.8% lidocaine patch is Scilex Holding Company’s lead marketed product and its core prescription topical pain therapy for localized neuropathic pain. The 1.8% strength is the key product feature, designed to deliver targeted lidocaine with a smaller systemic burden than oral pain drugs. Scilex reported $48.0 million in ZTlido net sales for 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-herpetic neuralgia pain relief\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZTlido is positioned for post-herpetic neuralgia, the long-lasting nerve pain that can follow shingles, and that keeps Scilex Holding Company’s pain strategy focused on one clear use case. In the U.S., about 1 in 3 people get shingles, and roughly 10% to 20% of those patients develop post-herpetic neuralgia.\u003c\/p\u003e\n\u003cp\u003eThat matters because the pain can last months or even years, so a targeted topical option like ZTlido fits a persistent, high-need market. The PHN indication is the anchor for Scilex Holding Company’s commercial pain portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-opioid pain portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eScilex Holding Company’s portfolio is built around non-opioid pain care, led by products like ZTlido and ELYXYB, so the brand is tied to opioid-sparing treatment. That matters in a U.S. pain market where about 51.6 million adults live with chronic pain and clinicians keep seeking safer options. The non-opioid theme is core to Scilex’s identity and product positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSP-102 Phase III gel corticosteroid\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSP-102 is Scilex Holding Company’s viscous epidural corticosteroid in Phase III for lumbosacral radicular pain, giving the company a late-stage asset beyond ZTlido. The program targets a large pain market and, if approved, could widen Scilex Holding Company’s product mix with a non-opioid option.\u003c\/p\u003e\n\u003cp\u003eFor the 4P mix, SP-102 strengthens Product by adding a differentiated injectable therapy, with late-stage development value that can support future pricing and provider interest. The key milestone is Phase III completion, which is the main value driver before any commercialization decision.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase III, late-stage pipeline asset\u003c\/li\u003e\n\u003cli\u003eEpidural use for radicular pain\u003c\/li\u003e\n\u003cli\u003eBroadens Scilex Holding Company beyond ZTlido\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSP-103 and SP-104 pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSP-103 is in Phase II for low back pain, while SP-104 has completed Phase I in fibromyalgia, giving Scilex Holding Company a broader pain pipeline beyond its current products. These are early-stage assets, so they add option value more than near-term sales, but they also widen the company’s addressable pain market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSP-103: Phase II, low back pain\u003c\/li\u003e\n\u003cli\u003eSP-104: Phase I completed, fibromyalgia\u003c\/li\u003e\n\u003cli\u003ePipeline expands into new pain indications\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZTlido Drives Sales, Pipeline Adds Scilex Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eScilex Holding Company’s Product mix is led by ZTlido 1.8% for post-herpetic neuralgia, with 2024 net sales of $48.0 million. The portfolio is still narrow, but SP-102, SP-103, and SP-104 add late-stage and early-stage upside across radicular pain, low back pain, and fibromyalgia.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZTlido\u003c\/td\u003e\n\u003ctd\u003eMarketed\u003c\/td\u003e\n\u003ctd\u003ePHN\u003c\/td\u003e\n\u003ctd\u003e$48.0M sales, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSP-102\u003c\/td\u003e\n\u003ctd\u003ePhase III\u003c\/td\u003e\n\u003ctd\u003eRadicular pain\u003c\/td\u003e\n\u003ctd\u003eLate-stage value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSP-103\u003c\/td\u003e\n\u003ctd\u003ePhase II\u003c\/td\u003e\n\u003ctd\u003eLow back pain\u003c\/td\u003e\n\u003ctd\u003ePipeline option\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSP-104\u003c\/td\u003e\n\u003ctd\u003ePhase I done\u003c\/td\u003e\n\u003ctd\u003eFibromyalgia\u003c\/td\u003e\n\u003ctd\u003eEarly-stage option\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDelivers a concise, company-specific breakdown of Scilex Holding Company’s Product, Price, Place, and Promotion strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCuts through Scilex’s 4Ps into a quick, actionable snapshot for fast decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eConsolidates primary, reputable sources to validate claims and speed due diligence with a clear, traceable reference trail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePalo Alto, California headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eScilex Holding Company’s corporate offices are in Palo Alto, California, its central operating base for executive, regulatory, and commercial work. Palo Alto sits in Santa Clara County and had 68,572 residents in the 2020 census, which puts Scilex close to Silicon Valley talent, investors, and life-science partners. That location supports fast decision-making and direct oversight of U.S. operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrescription pharmacy distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZTlido is a 1.8% lidocaine patch sold through prescription channels, so access depends on physician prescribing and pharmacy fulfillment. That makes the \"place\" strategy pharmacy-led, not direct-to-consumer. For a branded pain therapy, this fits the market: the key bottleneck is getting the script written and filled.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician-led access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eScilex Holding Company relies on physician-led access, so pain specialists and other prescribers, not walk-in retail buyers, drive use. That makes adoption hinge on clinical awareness, formulary access, and trust in prescribing data. In 2025, this channel also meant each new prescription had to pass through provider education first, which can slow volume but supports targeted demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eU.S. clinical trial sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eU.S. clinical trial sites are Scilex Holding Company’s key \"place\" channel: Phase I, II, and III work runs through investigator networks, not retail outlets. In 2025, U.S. sites still anchor the largest share of global trial activity, so enrollment speed, protocol fit, and retention drive how fast Scilex can move its pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMulti-site trials expand reach\u003c\/li\u003e\n\u003cli\u003eSites shape timeline and cost\u003c\/li\u003e\n\u003cli\u003eEnrollment is the main bottleneck\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eWholesaler and specialty pharmacy channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eScilex Holding Company uses wholesalers and specialty pharmacies to keep prescription products under tighter control, which fits biopharma distribution better than open retail channels. The model supports inventory planning, cold-chain handling where needed, and faster patient access for therapies that often need pharmacy coordination and prior authorization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eControlled distribution reduces leakage.\u003c\/li\u003e\n\u003cli\u003eSpecialty pharmacies improve patient access.\u003c\/li\u003e\n\u003cli\u003eWholesalers support inventory flow.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSpecialty drugs now account for more than half of U.S. drug spending, so this channel mix is standard for high-touch therapies. It also helps Scilex match demand more closely, since specialty pharmacies often manage refill timing, benefits checks, and shipment tracking.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScilex’s U.S.-First Access Strategy Prioritizes Prescriptions Over Shelf Space\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eScilex Holding Company’s place strategy is U.S.-centric: Palo Alto anchors corporate control, while physician-led prescribing and specialty pharmacies drive ZTlido access. That fits a prescription pain brand, where the main gate is the script, not the shelf.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePalo Alto HQ\u003c\/td\u003e\n\u003ctd\u003eSanta Clara County; 68,572 residents\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccess\u003c\/td\u003e\n\u003ctd\u003ePhysicians, wholesalers, specialty pharmacies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChannel effect\u003c\/td\u003e\n\u003ctd\u003eTargeted access, slower volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eScilex Holding Company Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Scilex Holding Company 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises.\u003c\/p\u003e\n\u003cp\u003eThis is the same ready-made, editable document you'll download immediately after checkout, fully complete and ready to use.\u003c\/p\u003e\n\u003cp\u003eYou’re viewing the exact file included in your order; the content here is the final version you'll own upon purchase.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-opioid pain messaging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eScilex Holding Company’s promotion leans on non-opioid pain relief, a clear fit in a market where the CDC reported 107,543 drug overdose deaths in 2023, with opioids involved in most cases. That message helps the Company stand out as a safer pain-care option and shapes its therapeutic positioning. It also supports adoption by patients and prescribers looking to reduce opioid exposure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZTlido brand awareness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZTlido, Scilex Holding Company’s 1.8% lidocaine patch, is the main brand-awareness engine in Promotion and anchors prescriber outreach for post-herpetic neuralgia, a neuropathic pain market. Marketing efforts aim to keep the brand top of mind with physicians and drive prescription adoption in a market where branded, non-opioid options matter. The goal is simple: lift recognition, then convert it into more scripts and repeat use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial announcements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eScilex Holding Company uses clinical trial announcements to promote SP-102, SP-103, and SP-104, with updates tied to Phase III, Phase II, and Phase I progress. These milestone disclosures keep clinician and investor attention on pipeline risk, timing, and readout potential. In 2025-2026, the three-stage update pattern signals a broad development pipeline, not a single asset story.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMedical affairs and education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eScilex Holding Company leans on medical affairs and physician education, not broad consumer ads, because specialty pain products need clinical evidence and clear dosing guidance. Its promotion centers on communicating trial data, safety, and therapeutic fit for products like ZTlido, ELYXYB, and GLOPERBA, where prescriber trust drives use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses clinical data first\u003c\/li\u003e\n\u003cli\u003eTargets prescribers, not mass media\u003c\/li\u003e\n\u003cli\u003eFits specialty pain selling\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInvestor and public communications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eScilex Holding Company uses press releases and investor updates to explain product progress, pipeline status, and corporate moves, which matters for a public biotech that depends on market trust and capital access. Clear disclosure helps investors track commercialization of its 3 marketed products and any pipeline changes, while also supporting liquidity and financing needs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eShares progress with the market fast\u003c\/li\u003e\n\u003cli\u003eExplains pipeline and corporate updates\u003c\/li\u003e\n\u003cli\u003eSupports visibility and capital access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScilex: Evidence-Led Pain Relief Gains Ground\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eScilex Holding Company’s promotion is evidence-led and prescriber-first, built around non-opioid pain relief and ZTlido’s brand equity. In 2025-2026, it kept attention on Phase III SP-102, Phase II SP-103, and Phase I SP-104, while medical education and press updates stayed central.\u003c\/p\u003e\n\u003cp\u003eThat fits a market shaped by 107,543 U.S. overdose deaths in 2023, with opioids involved in most cases. The message is clear: safer pain care, clinical proof, and repeat prescribing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverdose deaths\u003c\/td\u003e\n\u003ctd\u003e107,543, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZTlido role\u003c\/td\u003e\n\u003ctd\u003eMain awareness driver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline focus\u003c\/td\u003e\n\u003ctd\u003eSP-102, SP-103, SP-104\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrescription-only pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZTlido is prescription-only, so its price is set in the pharmacy-benefit channel, not the OTC shelf. That puts payer coverage, rebates, and prior authorization at the center of demand. In U.S. Rx markets, patients can face different out-of-pocket costs by plan, pharmacy, and copay design, so access terms can matter as much as the sticker price.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance-dependent out-of-pocket cost\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatient cost for Scilex Holding Company therapies can swing sharply by plan design, with copays, deductibles, and formulary tier driving the bill. For branded drugs, a nonpreferred tier or prior authorization can push costs higher, while 2025 Medicare Part D capped annual out-of-pocket drug spending at $2,000, limiting exposure for eligible patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRebate and discount structure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eScilex Holding Company does not disclose a fixed 2025 rebate rate, so realized price can sit below gross pharmacy price. In biopharma, net pricing is driven by payer rebates, wholesaler discounts, and distribution fees, so the gap can move with channel mix. That means Scilex’s take-home revenue is shaped more by contract terms than sticker price.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eValue-based non-opioid positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eScilex Holding Company can price non-opioid pain products on clinical value, not just cost. In the U.S., about 50 million adults live with chronic pain, so a therapy that improves safety, ease of use, and function can support premium pricing if it beats opioid or OTC options on outcomes and convenience.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrice tracks perceived clinical gain\u003c\/li\u003e\n\u003cli\u003eNon-opioid safety can justify premium\u003c\/li\u003e\n\u003cli\u003eBuyers compare efficacy and ease\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat matters because the market pays for unmet need, not labels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline assets not yet commercially priced\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSP-102, SP-103, and SP-104 are still development-stage assets, so Scilex Holding Company has no fixed commercial price for them yet. Their eventual pricing will depend on FDA approval, the final indication, payer coverage, and market access, not on an approved-product benchmark. As of 2025 filings, these programs remain pre-commercial, so price discovery is still ahead.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSP-102, SP-103, SP-104: no approved price yet\u003c\/li\u003e\n\u003cli\u003ePricing will follow approval and indication\u003c\/li\u003e\n\u003cli\u003ePayer access will shape net realized price\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZTlido 2025 Pricing: Payer-Driven, Not Sticker-Driven\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZTlido pricing in 2025 is mainly payer-driven, with gross price cut by rebates, discounts, and prior authorization. Patient out-of-pocket costs vary by plan, pharmacy, and tier, while 2025 Medicare Part D capped annual drug spending at $2,000. Scilex Holding Company’s net price depends more on access terms than sticker price.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2025 Price Signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZTlido\u003c\/td\u003e\n\u003ctd\u003eRx-only, payer-set\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet price\u003c\/td\u003e\n\u003ctd\u003eBelow gross price\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare Part D\u003c\/td\u003e\n\u003ctd\u003e$2,000 OOP cap\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234951930121,"sku":"sclx-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/sclx-marketing-mix.webp?v=1785731011","url":"https:\/\/dcfanalyst.com\/products\/sclx-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}